microarray-based assay Search Results


protein-based microarrays  (Fzmb GmbH)
90
Fzmb GmbH protein-based microarrays
Protein Based Microarrays, supplied by Fzmb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein-based microarrays/product/Fzmb GmbH
Average 90 stars, based on 1 article reviews
protein-based microarrays - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
tlr-focused, cdna-based microarray gearrays  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation tlr-focused, cdna-based microarray gearrays
Tlr Focused, Cdna Based Microarray Gearrays, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tlr-focused, cdna-based microarray gearrays/product/SuperArray Bioscience Corporation
Average 90 stars, based on 1 article reviews
tlr-focused, cdna-based microarray gearrays - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
peptide microarray–based screening for autoantibodies against epitopes of pre-defined 168 different antigens  (PEPperPRINT gmbh)
90
PEPperPRINT gmbh peptide microarray–based screening for autoantibodies against epitopes of pre-defined 168 different antigens
Peptide Microarray–Based Screening For Autoantibodies Against Epitopes Of Pre Defined 168 Different Antigens, supplied by PEPperPRINT gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptide microarray–based screening for autoantibodies against epitopes of pre-defined 168 different antigens/product/PEPperPRINT gmbh
Average 90 stars, based on 1 article reviews
peptide microarray–based screening for autoantibodies against epitopes of pre-defined 168 different antigens - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cell microarray based cell manipulation  (Silicon Biosystems)
90
Silicon Biosystems cell microarray based cell manipulation
Cell Microarray Based Cell Manipulation, supplied by Silicon Biosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell microarray based cell manipulation/product/Silicon Biosystems
Average 90 stars, based on 1 article reviews
cell microarray based cell manipulation - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
protein microarrays  (GenTel BioSurfaces)
90
GenTel BioSurfaces protein microarrays
Protein Microarrays, supplied by GenTel BioSurfaces, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein microarrays/product/GenTel BioSurfaces
Average 90 stars, based on 1 article reviews
protein microarrays - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
targetprint her2 gene expression  (Agendia BV)
90
Agendia BV targetprint her2 gene expression
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Targetprint Her2 Gene Expression, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/targetprint her2 gene expression/product/Agendia BV
Average 90 stars, based on 1 article reviews
targetprint her2 gene expression - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
microarray-based comparative genomic hybridization  (Kohlhammer GmbH)
90
Kohlhammer GmbH microarray-based comparative genomic hybridization
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Microarray Based Comparative Genomic Hybridization, supplied by Kohlhammer GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microarray-based comparative genomic hybridization/product/Kohlhammer GmbH
Average 90 stars, based on 1 article reviews
microarray-based comparative genomic hybridization - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
custom designed, oligo-based array comparative genomic hybridization microarray for large  (PreventionGenetics llc)
90
PreventionGenetics llc custom designed, oligo-based array comparative genomic hybridization microarray for large
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Custom Designed, Oligo Based Array Comparative Genomic Hybridization Microarray For Large, supplied by PreventionGenetics llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/custom designed, oligo-based array comparative genomic hybridization microarray for large/product/PreventionGenetics llc
Average 90 stars, based on 1 article reviews
custom designed, oligo-based array comparative genomic hybridization microarray for large - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
antigen microarray-based complement measurement  (Diagnosticum Inc)
90
Diagnosticum Inc antigen microarray-based complement measurement
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Antigen Microarray Based Complement Measurement, supplied by Diagnosticum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antigen microarray-based complement measurement/product/Diagnosticum Inc
Average 90 stars, based on 1 article reviews
antigen microarray-based complement measurement - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
platform rip-chip assay  (Ribonomics Inc)
90
Ribonomics Inc platform rip-chip assay
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Platform Rip Chip Assay, supplied by Ribonomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/platform rip-chip assay/product/Ribonomics Inc
Average 90 stars, based on 1 article reviews
platform rip-chip assay - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
semiconductor-based desktop microarray platform  (CombiMatrix)
90
CombiMatrix semiconductor-based desktop microarray platform
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Semiconductor Based Desktop Microarray Platform, supplied by CombiMatrix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/semiconductor-based desktop microarray platform/product/CombiMatrix
Average 90 stars, based on 1 article reviews
semiconductor-based desktop microarray platform - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
gene expression profiling mammaprint  (Agendia BV)
90
Agendia BV gene expression profiling mammaprint
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Gene Expression Profiling Mammaprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene expression profiling mammaprint/product/Agendia BV
Average 90 stars, based on 1 article reviews
gene expression profiling mammaprint - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if HER2+) cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if HER2+) cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques:

Only patients with HER2-negative disease were eligible for randomization to the VC arm. Patients were categorized as received allocated invention if they received at least one dose of experimental (or control) therapy.

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Only patients with HER2-negative disease were eligible for randomization to the VC arm. Patients were categorized as received allocated invention if they received at least one dose of experimental (or control) therapy.

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques:

Estimated pCR Rate for the signatures evaluated for V/C vs. concurrent HER2-negative control.

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Estimated pCR Rate for the signatures evaluated for V/C vs. concurrent HER2-negative control.

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques: Negative Control

Final predictive probabilities

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Final predictive probabilities

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques:

Selected Toxicities

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Selected Toxicities

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques: